Sign in
PIRS Stock Price, Chart, Stats & News
Pieris Pharmaceuticals, Inc.
Save
17.96M
Market cap
–
Current P/E
–
Forward P/E
PIRS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -1260.38% |
Operating margin | -23801.89% |
Pretax margin | 66162.26% |
Net margin | 66162.26% |
Effective tax rate | -0.21% |
ROA | -52.39% |
ROE | -68.54% |
D/E | – |
Interest coverage ratio | 65.70x |
PIRS valuation
P/E | – |
P/S | -338.78x |
P/B | 3.89x |
P/CF | -5.33x |
P/FCF | -0.64x |
P/OCF | -5.33x |
PEG | -2.82x |
EV multiple | 29.01x |
About
Pieris Pharmaceuticals, Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to discovering and advancing drugs based on its proprietary Anticalin technology. These Anticalin proteins are therapeutic, low-molecular-weight molecules derived from naturally occurring human lipocalins, which are found in blood plasma and other bodily fluids. The company's pipeline includes several key drug candidates: Respiratory: PRS-060/AZD1402: A lead Anticalin candidate currently in Phase II clinical trials, targeting IL-4Ra for the treatment of asthma and various inflammatory diseases.
Similar securities
Based on sector and market capitalization
Report issue